Dyne Therapeutics (DYN) News Today $13.78 -0.13 (-0.93%) Closing price 02/18/2025 04:00 PM EasternExtended Trading$13.78 0.00 (0.00%) As of 02/18/2025 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Consensus Recommendation of "Buy" by BrokeragesShares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) have earned an average rating of "Buy" from the thirteen brokerages that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a hold recommendation, ten have given a buy recommendation anFebruary 18 at 2:30 AM | marketbeat.comDyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific ConferenceFebruary 14, 2025 | globenewswire.comDyne Therapeutics (NASDAQ:DYN) Reaches New 52-Week Low - Should You Sell?Dyne Therapeutics (NASDAQ:DYN) Hits New 52-Week Low - Here's WhyFebruary 12, 2025 | marketbeat.comabrdn plc Purchases New Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)abrdn plc acquired a new stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the fourth quarter, according to its most recent filing with the SEC. The fund acquired 25,803 shares of the company's stock, valued at approximately $608,000. A number of other hedge funds and other institutionFebruary 12, 2025 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Trading Down 5% - Should You Sell?Dyne Therapeutics (NASDAQ:DYN) Shares Down 5% - Time to Sell?February 7, 2025 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Trading 7% Higher - Here's What HappenedDyne Therapeutics (NASDAQ:DYN) Shares Up 7% - Should You Buy?February 6, 2025 | marketbeat.comDyne Therapeutics, Inc. (DYN): Among the Best Rebound Stocks to Invest In NowFebruary 6, 2025 | insidermonkey.comJennison Associates LLC Reduces Stock Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN)Jennison Associates LLC lowered its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 10.0% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,211,915 shares of the company's stock after selling 135,0February 5, 2025 | marketbeat.comZacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and CardiolFebruary 3, 2025 | finance.yahoo.comDyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFebruary 3, 2025 | globenewswire.comDyne Therapeutics (NASDAQ:DYN) Sees Large Volume Increase - What's Next?Dyne Therapeutics (NASDAQ:DYN) Sees Unusually-High Trading Volume - Here's WhyJanuary 27, 2025 | marketbeat.comDyne Therapeutics: Moving Forward On 2 Key FrontsJanuary 24, 2025 | seekingalpha.comGuggenheim Reaffirms Buy Rating for Dyne Therapeutics (NASDAQ:DYN)Guggenheim reissued a "buy" rating on shares of Dyne Therapeutics in a research report on Friday.January 24, 2025 | marketbeat.comDyne Therapeutics, Inc. (NASDAQ:DYN) Receives Average Recommendation of "Buy" from BrokeragesDyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) has been assigned a consensus recommendation of "Buy" from the thirteen ratings firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation, ten have assigned a buy recommendation andJanuary 24, 2025 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Reaches New 52-Week Low - Here's What HappenedDyne Therapeutics (NASDAQ:DYN) Sets New 52-Week Low - Time to Sell?January 23, 2025 | marketbeat.comDyne Therapeutics Gains ‘Buy’ Rating Following FDA Fast Track Designation and Promising Trial ResultsJanuary 22, 2025 | markets.businessinsider.comDyne Therapeutics receives FDA Fast Track designation for DYNE-101January 21, 2025 | markets.businessinsider.comDyne Enjoys Fast Track Status for New TreatmentJanuary 21, 2025 | baystreet.caDyne Gets FDA Fast-Track Status for Neuromuscular Product CandidateJanuary 21, 2025 | marketwatch.comDyne's Myotonic Secures FDA's Fast Track Designation For Myotonic Dystrophy Type 1 TherapyJanuary 21, 2025 | markets.businessinsider.comDyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1January 21, 2025 | globenewswire.comDyne Therapeutics (NASDAQ:DYN) Hits New 1-Year Low - What's Next?Dyne Therapeutics (NASDAQ:DYN) Sets New 1-Year Low - Should You Sell?January 17, 2025 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Stock Price Down 4.7% - Here's WhyDyne Therapeutics (NASDAQ:DYN) Shares Down 4.7% - Should You Sell?January 16, 2025 | marketbeat.comDyne Therapeutics (DYN) Gets a Buy from RBC CapitalJanuary 14, 2025 | markets.businessinsider.comDyne Therapeutics' (DYN) Outperform Rating Reaffirmed at Royal Bank of CanadaRoyal Bank of Canada reaffirmed an "outperform" rating and issued a $45.00 price objective on shares of Dyne Therapeutics in a report on Tuesday.January 14, 2025 | marketbeat.comPositive Outlook for Dyne Therapeutics as DYN-101 Shows Promising Clinical Results and Strategic Regulatory AdvancementsJanuary 11, 2025 | markets.businessinsider.comDyne Therapeutics: Positive Phase 1/2 Trial Results for DYNE-101 Lead to Buy Rating and Overweight Stock RecommendationJanuary 11, 2025 | markets.businessinsider.comRBC remain buyers of Dyne Therapeutics after DM1 and DMD dataJanuary 10, 2025 | markets.businessinsider.comChardan Capital Reaffirms Buy Rating for Dyne Therapeutics (NASDAQ:DYN)Chardan Capital restated a "buy" rating and set a $50.00 price target on shares of Dyne Therapeutics in a research report on Friday.January 10, 2025 | marketbeat.comDyne Therapeutics stock tumbles following trial dataJanuary 10, 2025 | investing.comDyne Therapeutics presents new data from Phase 1/2 ACHIEVE trial of DYNE-101January 10, 2025 | markets.businessinsider.comDyne Therapeutics reports clinical data from its myotonic dystrophy type 1 treatmentJanuary 10, 2025 | msn.comDyne Therapeutics (NASDAQ:DYN) Earns "Buy" Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a research note on Friday.January 10, 2025 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Shares Gap Down - Here's WhyDyne Therapeutics (NASDAQ:DYN) Shares Gap Down - Here's WhyJanuary 10, 2025 | marketbeat.comDyne Therapeutics Reports Positive Data From ACHIEVE Study Of DYNE-101 In Myotonic Dystrophy Type 1January 10, 2025 | markets.businessinsider.comDyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101 in DM1 in H1 2026January 10, 2025 | globenewswire.comDyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 9, 2025 | globenewswire.comSarepta Therapeutics: A Promising Investment with Strategic Market Position and Innovative ARO-DM1 ProgramJanuary 8, 2025 | markets.businessinsider.comDyne Therapeutics shares jump ahead of clinical data reviewJanuary 8, 2025 | za.investing.comDyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ETJanuary 8, 2025 | globenewswire.comDyne Therapeutics (NASDAQ:DYN) Trading Down 3.7% - Here's WhyDyne Therapeutics (NASDAQ:DYN) Stock Price Down 3.7% - Here's WhyJanuary 3, 2025 | marketbeat.comDyne Therapeutics (NASDAQ:DYN) Shares Up 10.4% - What's Next?Dyne Therapeutics (NASDAQ:DYN) Shares Up 10.4% - Here's What HappenedJanuary 2, 2025 | marketbeat.comDyne Therapeutics, Inc. (NASDAQ:DYN) Receives Average Recommendation of "Buy" from AnalystsDyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report) has been assigned an average recommendation of "Buy" from the thirteen analysts that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a sDecember 30, 2024 | marketbeat.comGeode Capital Management LLC Acquires 84,760 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN)Geode Capital Management LLC lifted its stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 4.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,859,413 shares of the company's stock afterDecember 22, 2024 | marketbeat.comBarclays PLC Raises Stake in Dyne Therapeutics, Inc. (NASDAQ:DYN)Barclays PLC grew its stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 162.2% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 207,309 shares of the company's stock after acquiring an additional 128,246 sharesDecember 19, 2024 | marketbeat.comWellington Management Group LLP Reduces Stock Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN)Wellington Management Group LLP lowered its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 81.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 41,661 shares ofDecember 19, 2024 | marketbeat.comFranklin Resources Inc. Cuts Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN)Franklin Resources Inc. decreased its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 21.7% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,342,500 shares of the company's stock aDecember 18, 2024 | marketbeat.comState Street Corp Raises Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)State Street Corp increased its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 13.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,641,859 shares of the compaDecember 15, 2024 | marketbeat.comDyne Therapeutics initiated with an Outperform at BairdDecember 14, 2024 | markets.businessinsider.comDyne Therapeutics (NASDAQ:DYN) Upgraded to "Strong-Buy" at Raymond JamesRaymond James upgraded shares of Dyne Therapeutics to a "strong-buy" rating in a research report on Thursday.December 14, 2024 | marketbeat.com Get Dyne Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DYN and its competitors with MarketBeat's FREE daily newsletter. Email Address DYN Media Mentions By Week DYN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DYN News Sentiment▼0.200.44▲Average Medical News Sentiment DYN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DYN Articles This Week▼36▲DYN Articles Average Week Get Dyne Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DYN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Elanco Animal Health News Today Lantheus News Today Nuvalent News Today Cytokinetics News Today Verona Pharma News Today Grifols News Today TG Therapeutics News Today Krystal Biotech News Today SpringWorks Therapeutics News Today Biohaven News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DYN) was last updated on 2/19/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyne Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dyne Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.